Larisa J. Geskin, MD

Expertise in: 
Skin Cancer, Melanoma, Cancer Care
Board Certifications: 
Dermatology
Accepting New Patients
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Skin Cancer, Melanoma, Cancer Care, Skin Cancer Surgery, Skin Cancer, Cutaneous Lymphoma, General dermatology, Non-Melanoma Skin Cancer, Dermatologic Oncology

Academic Appointments

  • Associate Professor of Dermatology (in Medicine) at CUMC

Administrative Titles

  • Director, Cutaneous Oncology

Larisa Geskin, MD – Dermatologist at ColumbiaDoctors

Dr. Larisa Geskin is an Associate Professor of Dermatology at Columbia University Medical Center and Director of the Comprehensive Skin Cancer Center (CSCC) at the Division of Cutaneous Oncology in the Department of Dermatology.

She is a world-renowned specialist in the diagnosis and management of cutaneous lymphomas and other cancers of the skin. Her other areas of expertise include melanoma screening, prevention, medical and surgical therapy, and management of high risk for skin cancer populations. Dr. Geskin is using state-of-the-art methods in melanoma screening and surveillance including Mole Mapping (body mapping) and dermoscopy. She was involved in development of novel melanoma detection methods, including MelaFind among others. Dr. Geskin's team aims to provide multidisciplinary care to skin cancer patients, to conduct cutting edge clinical and basic science research, and to train medical students, residents and fellows in the area of cutaneous oncology.

Dr. Geskin completed her residency in Dermatology at University of Pittsburgh Medical Center (UPMC), and a two-year fellowship in cutaneous oncology at University of Pittsburgh Cancer Institute (UPCI) with Louis Falo, MD, PhD, Professor and Chairman, Department of Dermatology, UPMC, and with John Kirkwood, MD, Professor and Vice Chairman for Clinical Research, Director of the Melanoma Center at the UPCI.

She is a diplomat of the American Academy of Dermatology, member of the Society for Investigative Dermatology, the International Society for Cutaneous Lymphomas, and US Cutaneous Lymphomas Consortium. She authored over 30 peer-reviewed articles in the field of cutaneous oncology. Her research interest focuses on Cutaneous T-cell lymphoma (CTCL) and biomarkers discovery, genetic profiling and regulation, development of immunotherapy for melanoma and lymphoma.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Lawrence Hospital

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:
212-305-5293

Location(s)

CUMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Primary
ColumbiaDoctors Midtown
51 West 51st Street
New York, NY 10019
ColumbiaDoctors Tarrytown
155 White Plains Road
Tarrytown, NY 10591

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • 1995 Albert Einstein College of Medicine
  • MD, University of Pittsburgh School Of Medicine
  • Residency: 2001 University of Pittsburgh Medical Center
  • Fellowship: 2003 University of Pittsburgh Medical Center

Board Certifications

  • Dermatology
America's Top Doctor

Research

Grants

A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY OF TOPICAL SGX301 (SYNTHETIC HYPERICIN) AND FLUORESCENT BULB-LIGHT IRRADIATION FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (P&S Industry Clinical Trial)

May 1 2017 - May 30 2022

A DOUBLE BLIND, RANDOMIZED, VEHICLE CONTROLLED, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION, 0.5%, FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS (P&S Industry Clinical Trial)

Mar 8 2017 - Mar 8 2022

ROLE OF TOX AND STAT3 PATHWAYS IN THE PATHOGENESIS OF CUTANEOUS TCELL LYMPHOMA (Private)

May 1 2018 - Apr 30 2019

VALIDATION OF UV-RADIATION BIOMARKER PANEL FOR RISK OF UV-INDUCED SKIN CANCERS (Private)

May 1 2018 - Apr 30 2019

ROLE OF THE TOX-RUNX3 PATHWAY IN CUTANEOUS T-CELL LYMPHOMA (Private)

May 1 2017 - Apr 30 2018

A MULTIPLEX ASSAY FOR EARLY DETECTION OF CUTANEOUS T-CELL LYMPHOMA (Federal Gov)

Sep 1 2016 - Aug 31 2017

MOLECULAR PATHWAYS OF INERLEUKIN-13 IN CUTANEOUS T-CELL LYMPHOMA (Federal Gov)

Jul 1 2016 - Jun 30 2017

IDENTIFYING LONG NON-CODING RNAS THAT FUNCTION AS MICRORNA SPONGES DURING MELANOMA INITIATION (Private)

Feb 1 2016 - Jan 31 2017